Pfizer announced that it is proceeding with multiple ascending doses after completing single ascending dose dosing in a phase 1 study in healthy adults to evaluate the safety and tolerability of a new oral therapeutic antiviral for SARS-CoV-2, the virus that causes COVID-19.
Date: 03.2021 Source: pharmastar.co.uk